Compositions and methods for treatment and prevention of insulin resistance
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsRichard J. Johnson, Takahiko Nakagawa
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.2 to 5.5 mg/dl.
Claims21
A method of lowering uric acid levels in a patient suffering from insulin resistance comprising:
- administering to said patient a composition comprising a uric acid lowering agent according to a regimen effective to maintain said patient's average serum uric acid level at or below 5.5 mg/dl, wherein said uric acid lowering agent is a xanthine oxidase inhibitor, a uricosuric, a uricase, a peqylated uricase, a rasburicase, a urate channel inhibitor, or a URAT-1 blocker, wherein said administering treats said insulin resistance.
A method of lowering uric acid levels in a patient suffering from insulin resistance comprising:
- determining said patient's average serum uric acid level;
- and administering to said patient a composition comprising a uric acid lowering agent according to a regimen effective to maintain said patient's average serum uric acid level between 4.5 mg/dl and 5.5 mg/dl for at least 4 weeks, wherein said uric acid lowering agent is a xanthine oxidase inhibitor, a uricosuric, a uricase, a peqylated uricase, a rasburicase, a urate channel inhibitor, or a URAT-1 blocker, wherein said administering treats said insulin resistance.
A method of lowering uric acid levels in a patient suffering from insulin resistance comprising administering to said patient a composition comprising a uric acid lowering agent according to a regimen effective to maintain said patient's average serum uric acid level between 4.5 mg/dl and 5.5 mg/dl for at least 2 weeks, wherein said uric acid lowering agent is a xanthine oxidase inhibitor, a uricosuric, a uricase, a pegylated uricase, a rasburicase, a urate channel inhibitor, or a URAT-1 blocker, wherein said administering treats said insulin resistance.
Dependencies are inferred from the claim text.